Research Program

Summit for Stem Cell Foundation’s Research Program provides funding and support for innovative, evidence-based research that is primarily focused on Parkinson’s disease.

Summit strongly believes that regenerative medicine has the best potential to integrate and heal the human nervous system.

Summit believes that Parkinson’s disease is the easiest of neurodegenerative conditions to address first because it involves only one cell. The neurotransmitter, dopamine. To try to put it simply, the clock will be turned back on the symptoms of Parkinson’s disease by replacing the lost dopamine neurons. Once this cell therapy is successful, it will open the doors wide for other neurodegenerative conditions.

Summit, having successfully addressed the symptoms of Parkinson’s disease by launching Dr. Jeanne Loring’s autologous dopamine neuron replacement therapy into the private business sector, now turns its focus on new targets. The organization now looks to finding the answers to the longstanding questions for Parkinson’s disease and other neurodegenerative conditions:

“What is the CAUSE … ?” and “What is the CURE … ?”

And a new question:

  • Is Parkinson’s disease a single disease?
  • Or is Parkinson’s disease a syndrome with several different types of Parkinson’s disease?

Summit shares news and information on new & innovative research that looks outside the box on these complex issues. Currently, we are very excited about the work being done at the University of Cincinnati for the CCBP (Cincinnati Cohort Biomarker Program) under the guidance of Dr. Alberto Espay.

A few of the projects Summit monitors and provides information on are:

  • Aspen Neuroscience. The privately held company the science for the created to speed up journey from bench to bedside for the autologous dopamine neuron replacement therapy for Parkinson’s disease.
  • Bayer/Blue Rock Industries. This group is just beginning the clinical trial phase I for its allogeneic dopamine neuron replacement therapy for Parkinson’s disease here in the United States.
  • Dr. Jun Takahashi’s & Dr. Shinya Yamanaka’s allogeneic dopamine neuron replacement therapy for Parkinson’s disease in Japan already well into clinical trials.
  • Dr. Malin Parmer’s & Dr. Roger Barker’s dopamine neuron replacement therapy for Parkinson’s disease using embryonic-sourced neurons in Sweden.

Summit has a RESEARCH GRANT PROGRAM offering grants for qualifying researchers.

Summit also offers funding for FELLOWSHIPS for qualifying applicants.

Summit is committed to providing support and funding for research that eventually catapults answers for Parkinson’s disease into reality. Summit’s focus will remain primarily on Parkinson’s disease. However, the organization continues to monitor and share news of scientific progress (particularly in regenerative medicine) and other pertinent information about Parkinson’s disease and other neurodegenerative conditions.